Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Neutral 60.5%

Neg 0% Neu 60.5% Pos 0%

Barclays analyst Christopher Pasquale initiates coverage on Boston Scientific (NYSE:BSX) with a Equal-Weight rating and announces Price Target of $48.